Paper42049986
Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease.
Alasbali R and 17 others. Bone Marrow Transplant, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease. Papers, record 42049986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42049986
- Disease
- sickle cell disease163 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anemia, Sickle Cell | Major topic |
| Transplantation Conditioning | Major topic |
| Cyclophosphamide | Major topic |
| Thiotepa | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Humans | |
| Adolescent | |
| Female | |
| Male | |
| Adult | |
| Young Adult | |
| Graft vs Host Disease | |
| Child | |
| Treatment Outcome | |
| Prospective Studies |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT01850108 | Non-Myeloablative Conditioning and Bone Marrow Transplantation | Derived from the trial | Yes |
Source ClinicalTrials.gov
References26
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14985486 | Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. | N Engl J Med | 2004 | https://conductscience.org/library/papers/14985486 | PubMed |
| 2 | 26348889 | Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease. | Biol Blood Marrow Transplant | 2016 | https://conductscience.org/library/papers/26348889 | PubMed |
| 3 | 36385464 | Effects of Erythrocytapheresis Procedures on Delayed Bone Marrow Conversion in Sickle Cell Disease. | Clin Hematol Int | 2022 | https://conductscience.org/library/papers/36385464 | PubMed |
| 4 | 36044658 | Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism. | Blood | 2022 | https://conductscience.org/library/papers/36044658 | PubMed |
| 5 | 25696857 | Guidelines for quantifying iron overload. | Hematology Am Soc Hematol Educ Program | 2014 | https://conductscience.org/library/papers/25696857 | PubMed |
| 6 | 22967259 | High one year mortality in adults with sickle cell disease and end-stage renal disease. | Br J Haematol | 2012 | https://conductscience.org/library/papers/22967259 | PubMed |
| 7 | 28423290 | Sickle Cell Disease. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28423290 | PubMed |
| 8 | 27965196 | Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. | Blood | 2017 | https://conductscience.org/library/papers/27965196 | PubMed |
| 9 | 7993409 | Mortality in sickle cell disease. Life expectancy and risk factors for early death. | N Engl J Med | 1994 | https://conductscience.org/library/papers/7993409 | PubMed |
| 10 | 33534948 | Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres. | Br J Haematol | 2021 | https://conductscience.org/library/papers/33534948 | PubMed |
| 11 | 39939433 | The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. | Bone Marrow Transplant | 2025 | https://conductscience.org/library/papers/39939433 | PubMed |
| 12 | 25058217 | Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. | JAMA | 2014 | https://conductscience.org/library/papers/25058217 | PubMed |
| 13 | 26261241 | Low forced expiratory volume is associated with earlier death in sickle cell anemia. | Blood | 2015 | https://conductscience.org/library/papers/26261241 | PubMed |
| 14 | 30913039 | Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. | J Clin Invest | 2019 | https://conductscience.org/library/papers/30913039 | PubMed |
| 15 | 31495699 | Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. | Lancet Haematol | 2019 | https://conductscience.org/library/papers/31495699 | PubMed |
| 16 | 31782875 | Early viral reactivation despite excellent immune reconstitution following haploidentical Bone marrow transplant with post-transplant cytoxan for sickle cell disease. | Transpl Infect Dis | 2020 | https://conductscience.org/library/papers/31782875 | PubMed |
| 17 | 38817956 | Risks and benefits of cannabis as a pain control modality in patients with sickle cell disease. | Clin Hematol Int | 2023 | https://conductscience.org/library/papers/38817956 | PubMed |
| 18 | 33941871 | Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide. | Bone Marrow Transplant | 2021 | https://conductscience.org/library/papers/33941871 | PubMed |
| 19 | 38493482 | An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease. | Blood | 2024 | https://conductscience.org/library/papers/38493482 | PubMed |
| 20 | 29981283 | Clustering of end-organ disease and earlier mortality in adults with sickle cell disease: A retrospective-prospective cohort study. | Am J Hematol | 2018 | https://conductscience.org/library/papers/29981283 | PubMed |
Drugs5
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1200796 | ChEMBL |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1456 | ChEMBL |
| FLUDARABINE | CHEMBL1568 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1568 | ChEMBL |
| SIROLIMUS | CHEMBL413 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL413 | ChEMBL |
| MESNA | CHEMBL975 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL975 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42049986
GET https://conductscience.org/api/papers/v1/42049986/references?page=2